Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 642-647

  Kakodkar, Nisha C ^a   Peddinti, Radhika R ^b   Tian, Yufeng ^a   Guerrero, Lisa J ^a   Chlenski, Alexandre ^a   Yang, Qiwei ^a   Salwen, Helen R ^a   Maitland, Michael L ^a   Cohn, Susan L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Stroger Hospital   (United States)

Author keywords

Angiogenesis; Extracellular signal regulated MAP kinases; Neuroblastoma; Sorafenib

Indexed keywords

SORAFENIB;

ADRENAL TUMOR; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84864927220     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24004     Document Type: Article

References (27)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
2. Park JR, Eggert A, Caron H. Neuroblastoma biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65-86.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
4. Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-414.
5. Eggert A, Ikegaki N, Kwiatkowski J, et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900-1908.
6. Peddinti R, Zeine R, Luca D, et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 2007;13:3499-3506.
7. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-591.
8. Katzenstein HM, Rademaker AW, Senger C, et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5:4273-4278.
9. Shusterman S, Grupp SA, Barr R, et al. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001;7:977-984.
10. Chlenski A, Liu S, Cohn SL. The regulation of angiogenesis in neuroblastoma. Cancer Lett 2003;197:47-52.
11. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
12. Nilsson MB, Zage PE, Zeng L, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: Implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 2010;29:2938-2949.
13. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140.
14. Foley J, Cohn SL, Salwen HR, et al. Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res 1991;51:6338-6345.
15. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67:1716-1724.
16. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-574.
17. Chlenski A, Liu S, Baker LJ, et al. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res 2004;64:7420-7425.
18. Chlenski A, Guerrero LJ, Peddinti R, et al. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer 2010;9:138.
19. Khanna C, Jaboin JJ, Drakos E, et al. Biologically relevant orthotopic neuroblastoma xenograft models: Primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002;16:77-85.
20. Keir ST, Maris JM, Lock R, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 2010;55:1126-1133.
21. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-437.
22. Widemann BC, Fox E, Adamson PC, et al. Phase I study of sorafenib in children with refractory solid tumors: A children's Oncology Group Phase I Consortium trial. J Clin Oncol 2009;27:15s.
23. Roy CS, Karmakar S, Banik NL, et al. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Invest New Drugs 2010;28:812-824.
24. Chai H, Luo AZ, Weerasinghe P, et al. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol 2010;3:408-415.
25. Blenis J. Signal transduction via the MAP kinases: Proceed at your own RSK. Proc Natl Acad Sci USA 1993;90:5889-5892.
26. Misawa A, Hosoi H, Arimoto A, et al. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000;60:64-69.
27. Sandoval JA, Eppstein AC, Hoelz DJ, et al. Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: Profiling multiple targets of cancer kinase signaling. J Surg Res 2006;134:61-67.